Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Conditions: Accelerated/Blast-phase Myeloproliferative Neoplasm; Chronic-phase Myelofibrosis; IDH2 Mutation Interventions: Drug: Ruxolitinib; Drug: Enasidenib Sponsors: Michal Bar-Natan; Celgene Corporation; Incyte Corporation; Myeloproliferative Neoplasms Research Consortium; National Institutes of Health (NIH); National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials